LUGANO, December 1st, 2018 • Cerbios-Pharma SA (from now on “Cerbios”) is pleased to announce that Dr. Francesca Scarpitta has joined our team as Director of our High Potency Active Ingredients (HPAIs) Production units.
Cerbios is active in the HPAI arena since 1993, when the development of the first HPAI of category 4 (OEL<3ng/m3) started. In 2000 we successful passed the first FDA inspection for an HPAI production with no 483.
This new position was created in order to further strengthen our team in the development and manufacturing of HPAIs, where we have reached a significant exponential growth over the past decade.
As part of our strategy, we have constantly made and will make new investments to expand capacity as well as to keep the highest standard of innovative technology and quality in the industry, with the aim to be a major and recognized player as CDMO for Drug Substances needing high containment where the safety of the operators if essential.
“Dr. Scarpitta brings in a strong expertise and knowledge in the transfer of API manufacturing from R&D. Scale-up improvements following the development of the HPAI from clinical to commercial scale is one of her key competences“ confirms Dr. Gabriel Haering, CEO.
“Thanks to her contribution we will further boost Cerbios’ vision of excellence in the manufacturing segment of the HPAI contract manufacturing arena which is a fast growing activity with further new investments in the near future”.